• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
By JIM CRAMER Mar 07, 2019 | 07:00 AM EST
Stocks quotes in this article: AGN, JNJ

Stop being so cynical.

Do you know how many times I have had to say that to people in the last couple of decades? DECADES!

I think that one of the biggest impediments to making money in stock or index funds is cynicism.

Look, I get how screwed up our political system is, although that already brands me as a partisan because I can hear people saying I wouldn't be saying that if I loved President Trump.

Let's just take that off the table, though. Political cynicism has become a given if not a necessity to a rational life.

No, I am talking about things that matter to earnings -- and earnings aren't very political.

Specifically, I am talking about something that happened earlier this week that was met with intense cynicism: the approval of esketamine, a Johnson & Johnson (JNJ) drug, now known as Spravato for use against hardcore depression.

No sooner was it approved than I began to hear the jokes about Special K and how this is a club drug and how ridiculous it is that the FDA approved a drug that has been partnered with ecstasy to have a dynamite party time.

I find this kind of cynical chatter to be palpably horrendous, because as someone who is close to this issue I can tell you that the paucity of drugs to help severely depressed people is tragic. More than forty thousand people will take their lives this year in America -- we will be lucky if it is that low, and there is very little to offer people to try to allow them to blot out the negative thoughts that make it seem rational to commit suicide.

This nasal spray, which will be administered in tightly controlled circumstances, can save lives -- and that is really all that matters. The studies were conclusive that most people will be helped by Spravato, particularly at the point of ideation.

Now we know that this drug is not priced cheaply -- $4720 to $6785 in the first month and then reduced to $2360 to $3540 on a monthly basis -- but it is the first new mental health drug since Prozac was introduced 31 years ago.

I think that some of the cynical chatter stems from a misunderstanding of what mental illness is -- and I really wish there were no such term.

When my wife, Lisa, dislocated her elbow, they had to pull her arm out and then put it back into the joint. They gave her ketamine to deal with the pain.

It's the protocol. No one in the OR thought that Lisa wanted it to party hardy at a Hamptons bash. Now, because of the absurd, opaque way that hospitals work I have no idea how much it cost us.

But no matter. It was a necessity. She screamed from the pain, then she was quiet and then she laughed and asked if she behaved well or did she shriek in pain. Talk about instant effectiveness.

Now, though, JNJ wants it to help more than the elbow, JNJ wants to help another vital organ, the brain.

To me, the brain matters more than the elbow any day of the week. Who kills themselves over a painful elbow injury? But pain in the brain? When is this culture going to accept the concept that a brain illness is every bit as legit as a dislocated elbow? How many people have to kill themselves before we recognize that if there is something else out there, we should make it available?

That's why this approval is so important.

Last night Allergan (AGN) reported a huge failure on a pill that was meant to treat depression in a fast-acting way, as Esketamine does.

It's a reminder of how intractable brain illness is.

I salute JNJ for taking on the system to get this drug approved. The fact that it works is nothing less than a miracle -- and it certainly is a lot more instantaneous than the Prozac dysfunctional family of drugs.

To me, we should stop being so cynical. That's a win. And it will be a blockbuster win for JNJ shareholders, too -- a drug that I think could read a billion dollar status in two years or less, even as The Street thinks it might do $500 million by 2023. The Street thinks of it as a party Band-Aid, like another JNJ product. If you want to go front of the store, I think of it as a lifesaver.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Action Alerts PLUS, which Cramer co-manages as a charitable trust, was long JNJ.

TAGS: Investing | Stocks | Biotechnology | Healthcare | Pharmaceuticals | U.S. Equity | Global Equity |

More from Stocks

Accenture Forms a Bottom With Strengthening Indicators

Bruce Kamich
Jun 1, 2023 7:58 AM EDT

As we check the charts, I have two price targets.

The Cost of Investing in Retail Looks Steep

Ed Ponsi
Jun 1, 2023 7:00 AM EDT

Let's look at the risks to the sector and what could be a safe buy.

The AI Theme Destroyed the Economic Bears, But Now What?

James "Rev Shark" DePorre
Jun 1, 2023 6:37 AM EDT

About 90% of stocks are still struggling, but many market players are celebrating.

Watching Emotions on Wall Street

Helene Meisler
Jun 1, 2023 6:00 AM EDT

When investors get giddy right at the peak of a market move, it's time to pay attention.

AI Lightens Up a Bit but Market Remains Lopsided

James "Rev Shark" DePorre
May 31, 2023 4:29 PM EDT

Tech giants like Apple carry more weight as narrow market continues.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • 09:48 AM EDT CHRIS VERSACE

    AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login